Austco Healthcare Limited (AHC) Fair Value & Analysis
Healthcare · AU · Market cap A$84.3M
Fair value as of: Jun 24, 2026
Analysis
Austco Healthcare Limited (AHC) currently trades at A$0.2200, while our model-based Fair Value estimate is A$0.4100 — implying the stock looks roughly 86.4% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
About the company
Austco Healthcare Limited, together with its subsidiaries, engages in the business of development, manufacture, service, supply, and distribution of healthcare communications equipment and software in Australia, New Zealand, Asia, Europe, and North America. The company offers Tacera, an IP nurse call system; Medicom, a solution for nurse call system; Pulse Mobile which allows staff to manage nurse call functions on the go and trigger workflows remotely; clinical workflow that allows healthcare staff to communicate with ancillary departments, measure adherence to protocol, and control other systems; Built-in RTLS, a nurse call platform; enterprise reporting; and integration services. It is also involved in the marketing, sales, and installation of electronic healthcare communication systems. The company was formerly known as Azure Healthcare Limited and changed its name to Austco Healthcare Limited in November 2020. Austco Healthcare Limited was founded in 1986 and is headquartered i…
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Austco Healthcare Limited (AHC) undervalued?
What is the fair value of AHC?
What is the quality score of AHC?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.